Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stakeholders Offer Some Hatch-Waxman Creativity, Highlight Limits Of FDA Action

Executive Summary

Other proposals were broad in nature, and did not provide the agency with specific mechanisms to consider.

You may also be interested in...



FDA Looks Ahead To Complex Product-Specific Guidances

The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.

Exploring the US FDA's Upcoming Complex Generic Product-Specific Guidance Lists

The agency offers a glimpse of its regulatory agenda, although several have been carried over through multiple list updates.

Was Coronavirus A Factor In Cipla's Albuterol FDA Approval?

The agency said Cipla’s ANDA met all the requirements for approval, but also that there is increased demand for the products.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS122006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel